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Abstract
Background: The bioenergetic status of non-small cell lung cancer correlates with tumour aggressiveness. The voltage
dependent anion channel type 1 (VDAC1) is a component of the mitochondrial permeability transition pore, regulates
mitochondrial ATP/ADP exchange suggesting that its over-expression could be associated with energy dependent
processes including increased proliferation and invasiveness. To test this hypothesis, we conducted an in vivo gene-
expression meta-analysis of surgically resected non-small cell lung cancer (NSCLC) using 602 individual expression profiles,
to examine the impact of VDAC1 on survival.
Methodology/Principal Findings: High VDAC1 expression was associated with shorter overall survival with hazard ratio
(HR)=0.6639 (95% confidence interval (CI) 0.4528 to 0.9721), p=0.035352 corresponding to 52 versus 101 months. VDAC1
predicted shorter time to recurrence and was shown to be an independent prognostic factor compared with histology,
gender, age, nodal stage and tumour stage in a Cox multivariate analysis. Supervised analysis of all the datasets identified a
6-gene signature comprising HNRNPC, HSPA4, HSPA9, UBE2D2, CSNK1A1 and G3BP1 with overlapping functions involving
regulation of protein turnover, RAS-RAF-MEK pathway and transcription. VDAC1 predicted survival in breast cancer and
myeloma and an unsupervised analysis revealed enrichment of the VDAC1 signature in specific subsets.
Conclusions: In summary, gene expression analysis identifies VDAC1 gene expression as a predictor of poor outcome in
NSCLC and other cancers and is associated with dysregulation of a conserved set of biological pathways, which may be
causally associated with aggressive tumour behaviour.
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Introduction
Non-small cell lung cancer (NSCLC) is a common, largely
incurable cancer. In the early disease setting, surgical resection is
the standard of care and the benefit of adjuvant chemotherapy is
limited to 5–15% improvement in survival in stage II but not stage
I disease [1]. However relapse is frequent in stage I cancer with
37% of patients dying within five years, therefore there is a need to
identify reliable biomarkers of poor outcome in order to target
individuals for whom adjuvant or novel targeted therapy may
improve survival. Alteration in tumour metabolism is a hallmark of
cancer and high levels of hexokinase-dependent glucose trapping
in NSCLC evidenced by standardized uptake values on positron
emission tomography, is associated with shorter survival [2]. This
is seen in both early and advanced NSCLC [3,4].
The Voltage Dependent Anion Channel 1 (VDAC1) is an
outer mitochondrial membrane protein involved in the regulation
of ATP/ADP exchange and respiratory control [5]. VDAC1
interacts with proapoptotic BCL-2 family proteins [6,7]. Howev-
er, its role in regulating mitochondrial outer membrane
depolarization has been controversial [8,9,10]. Yet, emerging
data has identified a potential role for this protein in the
regulation of cell survival and for this reason we found it worthy
of further study. The permeability transition pore, which
comprises VDAC1, is directly regulated by the BH3-only
proapoptotic BCL-2 family member BAD [10] and regulates cell
survival. In contrast, the type II isoform (VDAC2) has been
identified as an antiapoptotic, negative regulator of BAK
[9,11,12]. The adenine-nucleotide translocator (ANT) which is
located in the inner mitochondrial is also considered to be a
major component of the permeability transition pore [13] and
along with VDAC it is believed to control mitochondrial
remodeling processes either directly or indirectly [14]. Recently,
the bacterial protein FilA [15] has been shown to regulate a
complex of VDAC1 with hexokinase II [16] which inhibits
apoptosis. A growing body of data suggests that hexokinase-
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14635VDAC interaction is anti-apoptotic [17], and disruption of this
interaction could be a strategy for inducing cell death [18,19].
VDAC-hexokinase complex has been reported to be regulated by
glycogen synthase kinase 3 beta [19] and AKT [20].
Cancer cells with low VDAC1 induced by RNA interference
exhibit a defect in cell growth in vivo [21]. Conversely, high levels
of VDAC1 expression levels may confer tumour cell selection
advantage by facilitating energy dependent processes such as
proliferation and invasiveness [22]. Although hexokinase II
expression has been linked to worse prognosis [23], to date there
have been no studies exploring the potential prognostic impact of
VDAC1 in patients with cancer. It was therefore hypothesized that
VDAC1 expression could impact survival following NSCLC
resection. Here, we show using gene expression meta-analysis
that VDAC1 overexpression is a strong, independent, poor
prognostic factor in early stage non-small cell lung cancer based
on combined analysis of multiple gene expression datasets.
VDAC1 overexpression is consistently associated with overexpres-
sion of 6 additional genes involved in survival signalling, protein
ubiquitination and ATP binding. This association is maintained
across multiple independent datasets and across different cancers
suggesting a potential role for these biological processes in
regulating tumour behaviour and therefore clinical outcome in
NSCLC.
Results
VDAC1 overexpression predicts shorter survival in NSCLC
In total, 8 independent NSCLC datasets were curated from
Gene Expression Omnibus (GEO), with a total of 602 micro-
arrays. In all datasets high expression of VDAC1 (upper tertile)
was associated with significantly shorter survival compared to that
of the lower tertile for VDAC1 expression, p=0.0353,
HR=0.6639 (0.4528 to 0.9721) (Figure 1A). The average overall
survival was 101.6 months in patients with the lowest VDAC1
tertile and 52 months in patients with highest VDAC1 tertile.
VDAC1 expression is an independent prognostic factor
To further explore the impact of VDAC1 on survival, we
carried out correlation and Cox regression analysis as well as
multivariate tests using PASW Statistics v.18 (SPSS: An IBM
company). High VDAC1 expression was shown to be an
independent prognostic variable for shorter survival p,0.001
level. Stage (p=0.013) and pT, (primary tumour), (p=0.022) also
proved to be independent variables correlated with survival, while
multivariate analysis showed that the combination of stage and
histology significantly influences patient survival (p=0.027). The
results from the Cox regression analysis can be seen in Table 1,
where VDAC1 has the most significant influence on survival
followed by pT and stage.
VDAC1 overexpression predicts shorter time to
recurrence following NSCLC resection
The influence of VDAC1 expression on time to relapse
following surgical resection was of interest as this clinical variable
is not confounded by therapy after relapse. It is therefore a more
accurate measure of prognostic significance. So we analysed only
the recurrence data and univariate analysis showed VDAC1 to
significantly predict time to recurrence (p,0.001). Information on
histological subtype, gender and age was available for all samples
and they were found to be not significant with p values of 0.35,
0.82 and 0.73 respectively. A summary of this analysis can be
found in Table 2. Similarly multivariate analysis ranked these
variables in the same order, with VDAC1 being the only
independent factor (p,0.001).
VDAC1 overexpression in Stage I samples leads to poor
survival
Information on stage was not available with all the datasets but
we analysed what we had access to. We had 89 Stage I samples
and the Kaplan-Meier plot for these patients is shown in Figure 1B;
p=0.0455, with an associated hazard ratio of 0.52 (0.1492–
0.7653). We found the correlation between VDAC1 expression
and survival to be very strong with p,0.001. Cox regression
analysis in stage 1 NSCLC, where adjuvant chemotherapy has not
been shown to improve patient outcome [24,25,26], revealed no
variables to be statistically significant but, similarly to the analysis
of all the data, VDAC1 was the most influential predictor of
survival (p=0.241), and was ranked above histology (p=0.344),
age (p=0.465), pT (p=0.970), pN, (nodal stage), (p=0.975) and
gender (p=0.999). The regression coefficient for VDAC1 was
29.18 indicating a very poor prognosis for patients with high levels
of VDAC1.The sample numbers were low for stages II and III
with 68 samples being Stage II and only 16 samples being Stage
III, this made it difficult to obtain statistically significant results.
The correlation between VDAC1 expression and survival in stage
II samples and Stage III samples was insignificant with p=0.853
and p=0.701 respectively. We had an inadequate number of
events in both stages to produce an accurate Kaplan Meier plot
with less than 10 incidences of death per category. The lack of
higher stage samples led us to focus on the output from Stage I
samples and from the combined data.
Figure 1. Survival curves for all data and for Stage I patients
based on VDAC1 expression. Figure 1A: Displays the Kaplan Meier
plot depicting patient survival dependent on high and low VDAC1
expression. The distinct difference in survival is visibly evident with the
median survival of high VDAC1 expressing patients being only half that
of low expressing patients. The curves are significantly different with
p=0.0353 by the logrank test. Figure 1B: The survival plot for stage I
patients. Again the difference in high andlow expressing samples is clear
with low VDAC1 patients having better survival rates. The logrank test
proves the curves are significantly different with p=0.0455. Stage I
samples follow the same pattern as all the combineddata from all stages.
doi:10.1371/journal.pone.0014635.g001
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gene signature
In order to gain an insight into the biology underlying the poor
prognosis of VDAC1 overexpressing NSCLC in vivo, an analysis
was conducted to identify which genes and gene networks are
consistently associated with high VDAC1 expression. A subset of 6
genes was identified in VDAC1 overexpressing NSCLC datasets
associated with significant differential expression in 50% or more
of the datasets. These genes were CSNK1A1, G3BP1, HNRNPC,
HSPA4, HSPA9 and UBE2D2; see Figure 2 where the difference
in the average expression of these genes when VDAC1 is low and
high is shown. As defined by the Gene Ontology Consortium [27]
HNRNPC, HSPA4, HSPA9 and UBE2D2 are involved in protein
ubiquitination pathways, and CSNK1A1 regulates EIF2 function.
HSPA9 is also involved in anti-apoptosis pathways while G3BP1 is
linked to Ras protein signal transduction and ATP dependent
DNA and RNA helicase activity. CSNK1A1, HSPA4 and HSPA9
are linked to ATP binding while HNRNPC is involved in RNA
and nucleotide binding. A summary of the GO terms for these
genes can be found in Table 3. HNRNPC, HSPA9, G3BP1 and
UBE2D2 were determined as being prognostic individually when
a univariate analysis was carried out on their expression levels and
survival time, the associated p values were 0.027, 0.002, 0.02 and
0.003 respectively.
Unsupervised analysis identifies VDAC1 as prognostic
and associated with a 6-gene signature
We also analysed the data without filtering for VDAC1
expression to reaffirm VDAC1 would be significantly differentially
expressed when expression levels of living and dead patients are
compared. Using this unsupervised method and ranking gene
expression according to overall survival time, VDAC1 was found
to be downregulated in patients with longer survival. Similarly the
6 genes that are regulated alongside VDAC1 behaved in the same
way, each of them were downregulated in samples from patients
that survived for a long period of time.
6-gene Signature association with VDAC1 overexpression
is independent of cancer type
To confirm the validity and potential biological relevance of the
6-gene signature covariant with VDAC1 we tested its discrimina-
tive power on an independent breast cancer dataset. A t-test was
performed comparing high and low VDAC1 expressing samples.
We found all 6 genes were upregulated when VDAC1 was highly
expressed. Similarly, expression was low when VDAC1 expression
was low and so our signature of genes covariant with VDAC1 in
NSCLC data exhibited the same expression patterns in breast
Table 1. Cox Regression analysis based on all patient data and VDAC1 expression.
Regression Coefficient Standard Error (SE) p-value Hazard Ratio
VDAC1 0.239 0.78 0.002 1.27 (1.09–1.48)
Tumour Type 0.044 0.137 0.75 1.045 (0.80–1.37)
Sex 20.078 0.238 0.745 0.925 (0.58–1.48)
Age 20.02 0.011 0.834 0.998 (0.98–1.02)
Stage 0.515 0.249 0.038 1.67 (1.03–2.73)
pT 1.623 0.695 0.019 5.07 (1.30–19.78)
pN 1.977 1.058 0.062 7.22 (0.91–57.45)
The influence VDAC1 and stage have on survival is evident from this figure with high VDAC1 expression inducing poor survival. VDAC1 is the most significant predictor
of survival time with stage and pT also displaying predictive power. The age of the patient, their gender or whether the tumour was squamous or adenocarcinoma
didn’t have a large effect on overall survival time.
doi:10.1371/journal.pone.0014635.t001
Table 2. Univariate Analysis of Time to Recurrence Data.
Type III Sum of Squares F Sig.
VDAC1 5103.97 14.55 0.000
Tumour Type 308.37 0.88 0.35
Sex 18.17 0.52 0.82
Age 41.47 0.118 0.73
When dealing with time to recurrence VDAC1 expression was again shown to
be the most significant variable at predicting time to recurrence. We found no
significant relationship between recurrence and tumour type, gender or age.
doi:10.1371/journal.pone.0014635.t002
Figure 2. Change in gene expression of our six significantly
differentially expressed genes linked to VDAC1 expression.
This chart shows the variation in gene expression of our differentially
expressed genes in the samples where VDAC1 expression is low and
when it is high. All the genes that collectively made up our signature
are upregulated and so increase when VDAC1 increases.
doi:10.1371/journal.pone.0014635.g002
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independent myeloma cancer dataset, performing a t-test on the
data which was split based on VDAC1 high and low expression.
We again found all of the 6 genes in our meta-signature returned
as being statistically significant at a p,0.001 level. Additional
validation was found through the analysis of the NCI60 cell lines
found in GSE2003. We again compared the samples based on
VDAC1 expression and found the 6-gene signature was conserved
in 8 of these cell lines, namely UACC62 and SK_MEL2
(melanoma), SF295 and SF539 (CNS), A498 and SNC12C (renal),
H23 and HOP62 (NSCLC). Analysing the NCI60 data for low
VDAC1 with low expression of the 6-gene signature identified 5
cell lines, CCRF-CEM, RPMI-8226 and K562B (leukaemia),
IGROV1 (ovarian) and H522 (NSCLC).
Validation of 6-gene signature using Principal
Components Analysis (PCA)
PCA helps to explain the variance in data and is a common
technique for dimensionality reduction in high dimensional data.
We performed the PCA on the NSCLC dataset GSE3141 and
found that although there were some outliers using the first
principal component, which accounted for as much of the
variability as possible, all 6 of the genes in our meta-signature
were in the top 1% based on PC1 component loadings. HNRNPC
and G3BP1 performed particularly well being placed fourth and
fifth in the list respectively.
Protein-Protein Interaction (PPI) Networks
Within the VDAC1 PPI network, using Yu et al’s [28]
categorisation, encoded proteins were classed as either hubs
(nodes with high degree values constituting vulnerable areas of the
network) and/or bottlenecks (those with high betweenness
centrality scores corresponding to key intersecting nodes). VDAC1
and four of the genes, CSNK1A1, HSPA4, HNRNPC and
UBE2D2 were considered as both hub-bottlenecks.
Clustering identified potential groups of genes operating in the
same pathways, processes or molecular complexes. Five of the
genes, G3BP1, UBE2D2, VDAC1, CSNK1A1 and HSPA4
belonged to four high-scoring clusters, the highest-ranked of these
containing both UBE2D2 and G3BP1. Functional analysis
revealed this cluster to be most significantly associated with the
SH2 domain, ATP binding sites, protein and protein tyrosine
kinase activity, autophosphorylation, DNA binding and transcrip-
tion factor activity. The next most significant VDAC1-related
cluster included HSPA4 which was enriched in nuclear lumen and
nucleoplasm components and RNA-binding and mRNA splicing
processes. VDAC1 itself was associated with a top-scoring cluster
functionally enriched in regulation of programmed cell death,
apoptosis, anti-apoptosis, nucleoplasm, intracellular organelle
lumen, transcription factor binding and repressor activities. The
cluster of which CSNK1A1 was a member was associated with
significant functionality in coated pit, endomembrane system,
endocytosis, endosome, binding and transport activities.
Shortest path analysis revealed a sub-network of 14 genes,
comprising the VDAC1 signature genes and key inter-connecting
partners including TP53, RASA1, GRB2, CBL, CSK, RAF1 and
KPNA2, see Figure 3. Only two of the genes HNRNPC and
CSNK1A1 were direct interactors; HNRNPC’s binding ability
being modulated by CSNK1A1-mediated phosphorylation.
Functional analysis revealed enriched processes primarily
associated with the VDAC1 target genes including ATP-binding
and nucleotide binding. Both the VDAC1-target and internal
shortest-path genes jointly participated in a number of significantly
enriched processes and pathways. These included signalling
processes (intracellular signalling cascade, RAS protein signal
transduction, small GTPase mediated signal transduction),
transport (nucleocytoplasmic transport, nuclear transport, intra-
cellular protein transport) and anti-apoptosis.
The genes providing internal links within the shortest-path
network were significantly enriched in signalling pathways, e.g.
Neurotrophin, IGF-1, Insulin, TPO, PDGF, EGF, Integrin, T Cell
Receptor, MAPK and ERKB. Further pathways identified
included: signalling of hepatocyte growth factor receptor,
transmembrane receptor protein tyrosine kinase signalling path-
way, enzyme linked receptor protein signalling pathway, sprouty
regulation of tyrosine kinase signals and IL-2 Receptor Beta Chain
in T cell Activation.
The main combined activities of the VDAC1 genes (CSNK1A1,
G3BP1, HSPA4, HSPA9 and UBE2D2) were focused on ATP and
nucleotide binding. Specific individual enriched functionality also
occurred, e.g. protein kinase activity and host-virus interaction
(associated with genes CSNK1A1 and VDAC1, respectively).
Interestingly, although less prominent within the PPI network,
the two non-hub-non-bottleneck genes, HSPA9 and G3BP1, were
enriched in distinct sets of functions. In the case of G3BP1, signal
transduction was highlighted (both small GTPase and RAS
protein) in conjunction with the connecting genes, RAF1 and
GRB2. HSPA9, in particular, was associated with two groups of
functions: protein targeting and transport (intracellular protein,
nuclear and nucleocytoplasmic) in conjunction with TP53 and
KPNA2; and negative regulation of cell death, apoptosis and
programmed cell death (together with TP53 and RASA1).
Table 3. A table representing the gene ontology processes that define the genes in our meta-signature.
Ubquitination/chaparone RAS Signalling P53 Regulation Translation RNA binding
HNRNPC X
UBE2D2 X
HSPA4 X
HSPA9 XX X
CSNK1A1 X
G3BP1 XX
Any genes involved in the same processes are easily identifiable and overlap is evident. Ubiquitination is the most common known process shared by the significant
genes; however RAS signalling and P53 regulation are also linked to 2 of the genes from the signature.
doi:10.1371/journal.pone.0014635.t003
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VDAC1 overexpression predicts shorter time to recurrence and
overall survival for NSCLC as evidenced from pooled gene
expression analysis. It is an independent prognostic factor as
evidenced from Cox regression analysis and predicts survival in
stage 1 disease, where subgroup analysis of randomized controlled
clinical trials of adjuvant chemotherapy have failed to show
clinical benefit [24,25,26]. A combined gene expression data
analysis approach has been employed to investigate the impact of
VDAC1 expression on survival, which was statistically significant
in all individual datasets examined.
Several recent studies analysing microarray data for prognostic
markers in NSCLC have produced inconsistent results [29]. The
distinct lack of overlap associated between these signatures reflects
instability and is attributed to small sample sizes with less than 200
samples used per study. Analysis of multiple datasets, for example
combined analysis of microarray gene expression datasets
addressing similar biological questions conducted at an interpre-
tational level by meta-analysis, can enable more accurate results.
Many studies propose methods for meta-analysis of microarray
data with the aim of identifying significantly differentially
expressed genes across studies using statistical techniques that
avoid the direct comparison of gene expression values [30]. The
evaluation of multiple datasets as employed in this study has been
shown to yield more reliable and valid results, because they are
based on large sample numbers and the individual bias caused by
each study is weakened [30].
It is not known why VDAC1 correlates with poor survival
outcomes. To understand the most relevant genetic features of
VDAC1 overexpressing NSCLC, we conducted a gene expression
meta-analysis [31,32] to identify a subset of genes (signature) that
were significantly enriched. We employed stringent statistical
criteria, combined with a large sample size to support the
identification of these VDAC1-covariant genes. VDAC1 and 6
gene signature was then validated across breast, myeloma and
NCI-60 datasets [33], suggesting enrichment of genes which were
independent of the type of cancer.
Interestingly, of the 6 genes identified as being conserved and
significantly differentially regulated in the high VDAC1 expressing
group, most were functionally linked to the regulation of protein
turnover. These genes included heat shock 70kDa protein 4
(HSPA4), ubiquitin-conjugating enzyme E2D 2 (UBE2D2), and
heat shock 70kDa protein 9 (mortalin/HSPA9), encoding a
glucose regulated 75 kilodalton protein previously reported as
correlating with poor survival in colorectal cancer [34]. HSPA9
also binds and inactivates wild type p53 [35], and regulates the
RAS RAF MEK pathway[36]. Similarly, p53 and RAS are targets
of GTPase activating protein (SH3 domain) binding protein 1
(G3BP1) [37], and shown to predict shorter survival in
oesophageal cancer [38]. Casein kinase 1, alpha 1 (CSNK1A1)
regulates protein turnover via initiation of translation via EIF2 and
participates in wnt signalling; a homologue CSKNK2A1 has been
previously identified as an independent predictor of survival in
squamous cell lung cancer [39]. Like G3BP1, heterogeneous
nuclear ribonucleoprotein C (C1/C2) or HNRNPC is involved in
RNA binding and transcription [40].
The PPI networks identified that the main combined activities
of the VDAC1 genes (CSNK1A1, G3BP1, HSPA4, HSPA9 and
UBE2D2) were focussed on ATP and nucleotide binding. Specific
individual enriched functionality also occurred, e.g. protein kinase
activity and host-virus interaction (associated with genes
CSNK1A1 and VDAC1, respectively). Interestingly, although less
prominent within the PPI network, the two non-hub-non-
bottleneck genes, HSPA9 and G3BP1, were enriched in distinct
sets of functions. In the case of G3BP1, signal transduction was
highlighted (both small GTPase and RAS protein) in conjunction
Figure 3. Shortest-path PPI analysis of VDAC1 target genes. These are shown with most-frequently occurring inter-connecting genes.
Shortest path analysis revealed a sub-network of 14 genes, comprising VDAC1 and the 6 differentially expressed genes associated with VDAC1
expression. The key inter-connecting partners included TP53, RASA1, GRB2, CBL, CSK, RAF1 and KPNA2. Only HNRNPC and CSNK1A1 interacted
directly.
doi:10.1371/journal.pone.0014635.g003
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particular, was associated with two groups of functions: protein
targeting and transport (intracellular protein, nuclear and
nucleocytoplasmic) in conjunction with TP53 and KPNA2; and
negative regulation apoptosis (together with TP53 and RASA1).
Conclusions
In summary, based on the poor prognosis associated with
overexpression of VDAC1 and the associated 6-gene signature,
methods to target this molecular subclass of NSCLC may be
effective in improve survival outcomes after surgery. We have
identified cell lines which have upregulation of the 6-gene
signature found in VDAC1 overexpressing NSCLC. Ongoing
work aims to target this signature to determine the effects on cell
viability utilizing the connectivity map. We propose that regulating
the expression of VDAC1 and/or genes with the 6-gene signature,
could provide a novel therapeutic strategy for targeting poor risk
patients with NSCLC.
Materials and Methods
Gene expression datasets
To conduct gene expression meta-analysis, a library of 8
NSCLC gene expression datasets was curated from NCBI Gene
Expression Omnibus (GEO) [41]: GSE8894, GSE3141 (array
type: HG-U133 Plus2.0), GSE6253, GSE4573 (array type: HG-
U133A), GSE6253 (array type: HG-U133B), GSE6253 (array
type: HG-U95Av2), GSE4716 (array type: GeneFilter Human
Microarray Release II) and GSE5123 (array type: PC Human
Operon v 2 21k). They had 602 samples in total and contained
gene expression information on primarily resected tumour samples
that had received no previous treatment. They were pre-processed
using R [42] and Bioconductor [43]. Normalization was carried
out using the RMA algorithm [44] as implemented in Biocon-
ductor. Data was base-two log-transformed where applicable.
Along with gene expression measurements, there were also
recordings of patient information, including age, sex, histology
and overall survival time, and in some cases stage, recurrence free
survival time, tumour stage (pT) and nodal stage (pN) were also
recorded. The genes that were found to be significantly
differentially expressed in the NSCLC datasets were then validated
in independent breast cancer datasets obtained from GEO:
GSE6434 containing HG-U95Av2 array data from 24 patients
who had received chemotherapy and GSE2034 with HG-U133A
array data from 286 samples. We also tested the meta-signature in
a myeloma dataset (GSE2658) with HG-U133 Plus2.0 array data
from 559 patients who had received chemotherapy. Further
validation was found through the analysis of the NCI60 cell line
panel (GSE2003) were we checked gene expression matched what
we found in our subset of significant genes. Additionally we
checked our results by carrying out principal components analysis
on the data in GSE3141.
Univariate and multivariate survival analysis
The distribution of VDAC1 expression was subdivided into
tertiles for each data set, corresponding to low, medium and high.
Kaplan-Meier curves were plotted using Prism (GraphPad
Software, San Diego California USA, www.graphpad.com) based
on survival data, comparing the highest versus lowest tertile for
VDAC1, initially these plots were produced for all data and then
only for stage I. Hazard ratios comparing low and high VDAC1
expressing samples were calculated. We carried out correlation
analysis between VDAC1 expression and survival time using
Spearman’s Rank correlation coefficient. We also performed
univariate and multivariate analysis using PASW (SPSS: An IBM
company), recurrence-free and overall survival were used as
clinical endpoints to assess prognostic significance of VDAC1; the
logrank ratio was considered to be significant if p,0.05. Cox
multivariate analysis was used to determine whether VDAC1 is an
independent prognostic variable in relation to 7 clinical variables:
age, gender, stage, histology, tumour size (pT), nodal stage (pN)
and survival.
Supervised microarray meta-analysis
We adopted the method termed meta-analysis of microarrays to
determine what genes were regulated alongside VDAC1 [45].
Each dataset was subdivided according to VDAC1 expression into
tertiles; we compared the top and bottom VDAC1 tertiles samples,
using TMeV [46]. Each gene was assessed for differential
expression using a two class t-test for each dataset with class 1
being low VDAC1 expression and class 2, high VDAC1
expression. Bonferroni’s correction was also used and this analysis
was carried out on all the 8 datasets. Bonferroni’s correction helps
minimise the likelihood of generating false positives. The number
of probes is vast with some datasets containing more than 54,000,
so to reduce our significant genes to a manageable list per dataset
we used a stringent cut off criteria where a gene was labelled as
significantly differentially expressed if the t-test returned a p value
of less than 0.001. The same hypotheses were tested in each
NSCLC dataset independently e.g. genes differentially expressed
based on VDAC1 expression. To enable multiple hypothesis
testing, we used a method that compares statistical measures and
Q values (estimated false discovery rates) calculated independently
from each dataset [32,47], where
Q~
estimated number of false positives ðÞ
number of called positives at a given p value ðÞ
Q~
p|n ðÞ
i
Where p is the probability, n is the total number of genes and i is
the sorted rank of the p value. The strict p value cut-off we applied
was carried forward when Q values were calculated. After ranking
the significantly differentially expressed genes based on their Q
value a direction and significance threshold of Q,0.10 was set to
define differential expression signatures from the already comput-
ed differential expression analysis. Having obtained an ordered list
of differentially expressed genes for each dataset genes were then
filtered based on the number of datasets in which they were
differentially expressed.. The genes that were defined as being
significantly differentially expressed were then validated in
independent breast cancer datasets (GSE6434 and GSE2034)
obtained from GEO with 24 and 286 samples respectively. We
also tested the meta-signature in a myeloma dataset (GSE2658)
with 559 samples. T-tests were performed on this additional data;
we compared high and low VDAC1 expressing samples to
determine if the genes from our signature were identified once
again. The same procedure was used on the NCI60 cell lines to
identify cell lines in which expression levels matched our signature.
Protein protein interaction network analysis
Using VDAC1 and the six associated SDE genes as seeds
together with their interactions found in the Human Protein
Reference Database (HPRD) [48], a parent PPI network
(including recursive interactions) was created using an in-house
Java-based program. Using these seed proteins as the initial depth
VDAC1 Predicts NSCLC Survival
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sampling. The resulting parent PPI network (9,266 gene nodes,
38,800) was then viewed, manipulated and analyzed in Cytoscape
[49]. Using the Network Analyzer plug-in [50] gene nodes were
then identified as either hubs or bottlenecks using the classification
of Yu et al [28]; the top 20% of nodes by degree value were
identified as hubs, the remainder as non-hubs. The same ranking
method was applied to the betweenness centrality metric to
identify bottleneck nodes. Each node in the PPI network was thus
classified in one of four categories: non-hub-non-bottlenecks (NH/
NB), hub-non-bottlenecks (H/NB), non-hub-bottlenecks (NH/B),
and hub-bottlenecks (H/B). Multiple shortest paths between the
seven genes were identified using the PeSca tool. Key shortest
paths were identified by considering direct connections between
the target genes, paths in which the target genes themselves acted
as inter-connectors, and the most frequently occurring genes
providing internal linkages. Modular functional enrichment
analysis of the gene clusters and shortest path network was carried
out using the online tool DAVID [51].
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